Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis — Cortese et al., Lancet Psychiatry 2018
Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis). Strong evidence. Lancet Psychiatry 2018;5(9):727–738. DOI 10.1016/S2215-0366(18)30269-4. Free full text in PubMed Central (PMC6109107) — open access, CC BY 4.0. Note: Trials were short (about 12 weeks), with too few data to judge effects at 6–12 months, and the authors rated certainty low or very low for many comparisons.
- What It Found
- Pooled 133 double-blind trials of seven ADHD medicines. Over about 12 weeks, all seven reduced clinician-rated ADHD symptoms in children and adolescents compared with placebo (methylphenidate SMD −0.78, 95% CI −0.93 to −0.62), and four of the five tested in adults did (amphetamines SMD −0.79, −0.99 to −0.58). Weighing benefit against side-effects, the authors favoured methylphenidate for children and amphetamines for adults as first choices for short-term treatment.
- Why It Matters Here
- Backs up the ADHD practitioner directories and organisations in chapter 09 (CHADD, ADDA, AADPA, ADHD UK) and the ADHD books and webinars in chapter 10 that explain medication choices: a specialist assessment opens the door to medicines with well-tested short-term benefit.
Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis). Strong evidence. Lancet Psychiatry 2018;5(9):727–738. DOI 10.1016/S2215-0366(18)30269-4. Free full text in PubMed Central (PMC6109107) — open access, CC BY 4.0. Note: Trials were short (about 12 weeks), with too few data to judge effects at 6–12 months, and the authors rated certainty low or very low for many comparisons.